Navigation Links
Shire plc: Continued Strong Product Sales Performance in Q3: On Track to Deliver Significant 2011 Earnings Growth
Date:10/28/2011

re. VYVANSE sales were up 32% and INTUNIV sales grew 50%.

The investment in our product portfolio is already delivering benefits and we believe our R&D pipeline will provide important therapies to patients around the world. In addition to initiating Phase 3 clinical trials for VYVANSE as adjunctive therapy in Major Depressive Disorder (MDD), we're releasing highlights of exploratory data showing that cognition and executive function were improved in patients with MDD taking VYVANSE as adjunctive therapy. We've also released positive new clinical data related to our Phase 3 European ADHD clinical program. Overall, we've increased investment in our R&D programs by 21% compared to Q3 2010, and still generated good earnings growth and strong cashflows.

Over the course of the year we've seen market expectations for Shire's 2011 earnings rise, with further increases in the last quarter. After these good third quarter results, and after taking account of the lower royalty income that we will be recording in future periods, we remain on track to meet these increased expectations. We anticipate that this will be another very good year for Shire as we deliver strong sales and continue our investment program for sustained future growth."

FINANCIAL SUMMARY

Third Quarter 2011 Unaudited Results

Q3 2011 Q3 2010 Non Non US GAAP Adjustments GAAP US GAAP Adjustments GAAP $M $M $M $M $M $M Total revenues 1,086 - 1,086 874 - 874 Operating income 255 86 341 156 142 298 Diluted earnings per ADS $1.02 $0.26 $1.28 $0.52 $0.64 $1.16

  • Product sales were up 28% to $1,018 million (Q3 2010: $794 million) as our existing products continued to demonstrate strong growth even when compared to the very good performance in Q3 2010. In Q3 2011 we recognized the first full quarter of DERMAGRAFT® sales which contributed six percentage points to product sales growth. On a constant exchange
    '/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Related biology technology :

1. NHS Northamptonshire Chief Executive John Parkes Accepts Visiting Professorship
2. FDA Approves Shires FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE)
3. Shires Quarterly Revenues Grow by 25% to $1 Billion for the First Time
4. Shire Files Lawsuits Against Watson and Roxane for Infringement of VYVANSE(R) (lisdexamfetamine dimesylate) Patents
5. Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)
6. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
7. Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
8. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
9. Reportlinker Adds Shire plc: PharmaVitae Profile
10. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
11. Shire plc - Statement re ProAmatine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... a well-known optical phenomenon called thin-film interference, a ... the ability to "paint" ultra-thin coatings onto a ... making future, flexible electronic devices, creating advanced solar ... ships and spacecraft with extremely lightweight decorative logos. ... it becomes iridescent, revealing a myriad of colors ...
(Date:9/30/2014)... 30, 2014 Shimadzu Scientific Instruments ... easy-to-use and highly precise tool for measuring displacement ... elongation. With 1000-mm maximum movement distance, the DSES-1000 ... a gauge length of 10 mm. In addition, ... above 50-mm stroke and within +/- 100 µm ...
(Date:9/30/2014)... , Sept. 30, 2014  RegeneRx Biopharmaceuticals, ... announced that it has received a Canadian Patent ... Actin-Sequestering Peptides.  This patent includes claims using thymosin ... other actin-sequestering peptides for these purposes.  The patent ... RegeneRx Biopharmaceuticals, Inc. ( www.regenerx.com ) ...
(Date:9/30/2014)... 2014  KemPharm, Inc., a clinical-stage specialty pharmaceutical ... proprietary new molecular entity (NME) prodrugs, announced today ... (USPTO) issued U.S. Patent No. 8,816,083 to KemPharm ... Acid Derivatives and Heteroaryl Carboxylic Acid Conjugates of ... The patent, which extends through 2032, ...
Breaking Biology Technology:Taking thin films to the extreme 2Shimadzu’s New Long-Travel Extensometer Increases Precision for Soft Material Testing 2RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2KemPharm, Inc. Receives Patent from the USPTO for Novel Prodrug of Hydromorphone, KP511 2
... Europe Aviation is very proud to receive its accreditation," ... "For more than 10 years our vision in the ... and BAR) has been to operate in a safe ... in France as well as facilities in East Europe, ...
... progress of plant-derived insulin program, scheduled to ... TSX symbol: SBS, CALGARY, July 29 /PRNewswire-FirstCall/ ... a portfolio of therapeutic,proteins for metabolic and cardiovascular ... New Drug (IND) application for,safflower-produced recombinant human insulin ...
... First Fully-Automated Random Access ... AACC Meeting, SUNNYVALE, Calif., July 29 ... Infinity-48 high-throughput system,at the 2008 American Association ... The newest addition to Cepheid,s GeneXpert family ...
Cached Biology Technology:First Program Addressing Aircraft Industry Sustainability Awards Accreditation To Five Global Companies 2First Program Addressing Aircraft Industry Sustainability Awards Accreditation To Five Global Companies 3First Program Addressing Aircraft Industry Sustainability Awards Accreditation To Five Global Companies 4SemBioSys submits IND for safflower-produced insulin to U.S. FDA 2SemBioSys submits IND for safflower-produced insulin to U.S. FDA 3Cepheid Introduces GeneXpert(R) Infinity-48 System at 2008 American Association of Clinical Chemistry Meeting 2Cepheid Introduces GeneXpert(R) Infinity-48 System at 2008 American Association of Clinical Chemistry Meeting 3Cepheid Introduces GeneXpert(R) Infinity-48 System at 2008 American Association of Clinical Chemistry Meeting 4
(Date:9/30/2014)... New England Journal of Medicine reports positive results ... crizotinib against the subset of lung cancer marked by ... of 50 patients with advanced non-small cell lung cancer ... was 72 percent, with 3 complete responses and 33 ... takes for the disease to resume its growth after ...
(Date:9/30/2014)... in urban and farm runoff in Hawaii is causing ... , The study, published Tuesday in the peer-reviewed ... the runoff ends up in algae that the turtles ... eyes, flippers and internal organs. , Scientists at Duke ... and Atmospheric Administration (NOAA) conducted the study to better ...
(Date:9/30/2014)... want your doctor to know what goes wrong with your ... idea to know what "normal" actually is. That,s where a ... the FASEB Journal comes in. In ... key set of molecules that can help scientists "see" which ... What,s more, they found never-before-detected gene activity and that men ...
Breaking Biology News(10 mins):NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer 2Pollution linked to lethal sea turtle tumors 2Pollution linked to lethal sea turtle tumors 3Scientists identify which genes are active in muscles of men and women 2
... and zanamivir, are highly effective when given as ... the influenza virus, according to an analysis of ... Research Center, University of Michigan and University of ... the American Journal of Epidemiology. The analysis also ...
... for granted when it is carried out by the ... when scientists devise new ways for molecules to self ... , Researchers with the Macromolecules and Interfaces Institute (MII ... development in the online issue for the Journal of ...
... Center have identified a subgroup of hard-to-treat breast cancers ... used in the treatment of breast tumors. They ... which may help identify patients most likely to benefit ... in a clinical trial anticipated to begin at the ...
Cached Biology News:Antivirals effectively curb influenza virus 2Antivirals effectively curb influenza virus 3Molecular signature may identify cisplatin-sensitive breast tumors 2Molecular signature may identify cisplatin-sensitive breast tumors 3
4-Hydroxy-3-nitrophenylacetyl hapten is conjugated to KLH (Keyhole Limpet Hemocyanin) lysine through amide bonds....
Estrogen Receptor (ER) Competitor Assay Kits Green for Estrogen Receptors-alpha and -beta (ER-Alpha and ER-Beta) are ideal for screening novel estrogen receptor binding compounds and endocrine disrup...
Human Aminopeptidase P2/XPNPEP2 Affinity Purified PAb ENTREZ GeneID: 7512...
in vitro Translation, Accessory Products...
Biology Products: